We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Noninvasive Occlusion Spectroscopy Assessed for Blood Banks

By LabMedica International staff writers
Posted on 05 Jun 2013
The feasibility of using noninvasive occlusion spectroscopy method in a blood bank to determine hemoglobin (Hb) levels has been compared with standard methods. More...


The tests used for anemia screening in blood donors are based on phlebotomy samples, leading to discomfort and complaint, which can be avoided by using occlusion spectroscopy that makes the procedure more comfortable and could therefore contribute to greater donor retention.

Hematologists at the University of Campinas (Brazil) enrolled 205 consecutive volunteer blood donors of whom, 136 were males and 69 females with an age range of 18 to 65 years, with the median at 32 years. Samples were collected by fingerstick and venous puncture to determine Hb level by a photometer (Hb-F) and automatic blood analyzer (Hb-V) and compared to the noninvasive Hb (Hb-NI) determination by occlusion spectroscopy (Orsense Ltd.; Nes Ziona, Israel).

The Hb-NI determination was performed by pressure applied by a ring-shaped multiwave length sensor probe containing a pneumatic cuff that temporarily occludes the blood flow in the base of the finger and generates a strong optical signal, yielding a high signal-to-noise ratio that is wholly blood specific. Analysis of the signal in the wavelength range of 600 to 1,500 nm provides the necessary sensitivity for measuring Hb concentration and pulse rate. The test is performed in 90 seconds, and is far more comfortable for the donors than phlebotomy.

The results obtained with Hb-F using the Hemocue Hb201+ (Ängelholm, Sweden) showed significant above value differences in the general group as well as when stratified by sex, weight, and age groups, than those obtained with Hb-V using the CellDyn Ruby automatic analyzer (Abbott Laboratories, Abbott Park, IL, USA ). There were significant differences between Hb-NI that were below Hb-V values when measured using the NBM200 occlusion spectroscopy method, but only in females and weight levels between 61 kg to 70 kg.

The authors concluded that the Hb-NI is a feasible and noninvasive to screen donors. It is safe, easy to perform, and quick and does not require extremely specialized technicians. It may also be used in mobile units due to its portability and may be used with power supply or batteries, which allows approximately 100 tests per battery. An issue that should be considered is the higher cost per test of Hb-NI, about USD 1.13 compared to the Hb-F at around USD 0.50. The study was published in the April 2013 edition of the journal Transfusion.

Related Links:

University of Campinas
Orsense Ltd.
Hemocue
Abbott Laboratories


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.